Vivos Therapeutics VVOS Estimates

NASDAQ VVOS
$0.19 +0.01 (+4.46%)
As of: Sep 9, 2026 · 11:21 AM EDT
Analyst Estimates

Vivos Therapeutics, Inc. Revenue Estimates

Periods 18
Next Period Q3 26
Consensus 6.31 M

Analysts expect Vivos Therapeutics, Inc. to report revenue of 6.31 M for Q3 26, against a range of 5.82 M to 6.81 M. The most recent reported quarter, Q2 26, came in at 5.15 M, a 13.9% miss against the 5.98 M consensus.

Metric Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28
Reported (Actual) 3.90 M3.70 M3.02 M3.82 M6.78 M3.82 M5.14 M5.15 M--------
High Estimate 4.22 M3.87 M3.79 M3.66 M4.86 M8.23 M4.53 M6.27 M6.81 M7.35 M5.56 M6.59 M9.29 M9.93 M8.49 M8.74 M
Low Estimate 3.65 M3.41 M3.14 M3.40 M4.05 M6.82 M3.86 M5.69 M5.82 M6.48 M4.79 M5.92 M8.43 M8.63 M6.95 M7.88 M
Consensus Estimate 3.94 M3.64 M3.46 M3.53 M4.45 M7.53 M4.19 M5.98 M6.31 M6.91 M5.18 M6.25 M8.86 M9.28 M7.72 M8.31 M
Analyst Estimates

Vivos Therapeutics, Inc. Earnings Per Share (EPS) Estimates

Periods 18
Next Period Q3 26
Consensus -0.30

Analysts expect Vivos Therapeutics, Inc. to report earnings per share of -0.30 for Q3 26, against a range of -0.32 to -0.28. The most recent reported quarter, Q2 26, came in at -0.31, a 22.5% beat against the -0.40 consensus.

Metric Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28
Reported (Actual) -0.400.41-0.45-0.55-0.49-0.58-0.52-0.31--------
High Estimate -0.59-0.36-0.37-0.35-0.45-0.43-0.43-0.37-0.28-0.24-0.54-0.55-0.29-0.20-0.58-0.49
Low Estimate -0.69-0.40-0.39-0.39-0.55-0.53-0.49-0.43-0.32-0.26-0.64-0.59-0.35-0.22-0.62-0.59
Consensus Estimate -0.64-0.38-0.38-0.37-0.50-0.48-0.46-0.40-0.30-0.25-0.59-0.57-0.32-0.21-0.60-0.54